ADUS Addus HomeCare Corporation
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. Its Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. Its Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who require assistance during an illness or after hospitalization. The company serves federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Addus HomeCare (NASDAQ: ADUS)
›
Addus HomeCare (NASDAQ: ADUS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 5,982 employees.
The shares were at 121.07 USD on 19 November 2026, up 7.9% over 52 weeks. Its 52-week range is 87.95 USD to 131.59 USD: the price is 8.0% below the high and 37.7% above the low.
At a market capitalisation of 2.26B USD, it trades at 20.1 times trailing earnings and 15.9 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.7, a discount of 15% for ADUS.
Addus HomeCare reports return on equity of 8.8%, an operating margin of 10.4% and revenue up 7.0% year over year.
It holds more cash than debt, a net cash position of 31.16M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 141.46 USD is 16.8% above the current price. The next earnings report is expected on 22 February 2027.